Lung CarcinomaPhase 3NCT02856581
Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes
A Phase 3 study testing Varenicline and Tobacco Cessation Counseling in people with Lung Carcinoma, run by Alliance for Clinical Trials in Oncology at 374 sites in United States.
Trial summary
This randomized phase III trial studies how well management of a tobacco treatment intervention works in reducing surgical complications in patients with newly diagnosed lung cancer who smoke cigarettes. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Carcinoma
- What is being tested?
- Varenicline and Tobacco Cessation Counseling
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 23 participants
- Where
- 374 sitesUnited States
- Study dates
- 29 Sep 2017to 15 Apr 2022
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
- Eligible patients will have a new diagnosis of lung cancer and have sought a surgical consult relating to this diagnosis
- Surgery must be scheduled no sooner than 10 days after randomization and no more than twelve weeks after randomization
- Have smoked daily or nearly every day in the previous 6 months up to the date of surgical consult AND have smoked at least one puff in the previous 7 days
- Motivated to stop smoking, as indicated by a score of 6 or above on the Contemplation Ladder
- Within the 30 days before registration, no use of: 1) any pharmacologic treatment for smoking cessation, including bupropion or nicotine replacement therapy; 2) any nicotine delivery system (i.e., e-cigarettes and vape products); or 3) be enrolled in any formal behavioral treatment program for tobacco dependence as determined by patient report
- No allergies to and not currently using varenicline
- No suicidal thoughts as indicated by a positive (1+) response to the PHQ9
- No active untreated clinically significant psychiatric condition (psychosis, bipolar disorder, or depression)
- Negative pregnancy test (serum or urine) done =< 7 days prior to registration, for women of childbearing potential only
- A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
- No unstable angina, myocardial infarction, or coronary angioplasty within the past 3 months or an untreated cardiac dysrhythmia
- No history of seizures
- No unstable neurologic, hepatic, renal, cardiovascular, lymphatic, or metabolic disease
- Not currently on renal dialysis or has a history of significant renal impairment
- No recent history (=< 90 days) of substance abuse (outside of tobacco) defined by National Institute on Alcohol Abuse and Alcoholism (NIAAA) as:
- If male, drinking > 14 alcoholic beverages per week for past 1 month
- If female, drinking > 7 alcoholic beverages per week for past 1 month
- Use of cocaine, heroin, club drugs (i.e., 3,4-methylenedioxymethamphetamine (MDMA)/"ecstasy"), methamphetamine, or hallucinogens (e.g., lysergic acid diethylamide [LSD]) at any time during the past 1 month
- Use of marijuana on a weekly basis for the past 1 month
- Patients must be able to complete study questionnaires in English
- No other household member or relative participating in the study
- No known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder study adherence
- Calculated creatinine clearance >= 30 mL/min * For females, use 85% of calculated creatinine clearance (CrCl) value
Trial locations and contacts
374 sites in 1 country.
300 sites in 1 country
United States300 sites
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
Alliance Cancer Center
Alliance, Ohio, 44601
American Fork Hospital / Huntsman Intermountain Cancer Center
American Fork, Utah, 84003
Community Hospital of Anaconda
Anaconda, Montana, 59711
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109
Northwest Community Hospital
Arlington Heights, Illinois, 60005
PCR Oncology
Arroyo Grande, California, 93420
Piedmont Hospital
Atlanta, Georgia, 30309
MultiCare Auburn Medical Center
Auburn, Washington, 98001
Rocky Mountain Cancer Centers-Aurora
Aurora, Colorado, 80012
The Medical Center of Aurora
Aurora, Colorado, 80012
University of Colorado Hospital
Aurora, Colorado, 80045
Rush - Copley Medical Center
Aurora, Illinois, 60504
Virginia Mason Bainbridge Island Medical Center
Bainbridge Island, Washington, 98110
Saint Alphonsus Medical Center-Baker City
Baker City, Oregon, 97814
Eastern Maine Medical Center
Bangor, Maine, 04401
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
Medical Center of Baton Rouge
Baton Rouge, Louisiana, 70816
Ochsner High Grove
Baton Rouge, Louisiana, 70836
Indu and Raj Soin Medical Center
Beavercreek, Ohio, 45431
UM Upper Chesapeake Medical Center
Bel Air, Maryland, 21014
Overlake Hospital Medical Center
Bellevue, Washington, 98004
Central Vermont Medical Center/National Life Cancer Treatment
Berlin Corners, Vermont, 05602
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
Billings Clinic Cancer Center
Billings, Montana, 59101
Saint Vincent Healthcare
Billings, Montana, 59101
Saint Vincent Frontier Cancer Center
Billings, Montana, 59102
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Saint Elizabeth Boardman Hospital
Boardman, Ohio, 44512
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Parkland Health Center-Bonne Terre
Bonne Terre, Missouri, 63628
Boulder Community Hospital
Boulder, Colorado, 80301
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado, 80304
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Lafayette Family Cancer Center-EMMC
Brewer, Maine, 04412
Ocean Medical Center
Brick, New Jersey, 08724
IHA Hematology Oncology Consultants-Brighton
Brighton, Michigan, 48114
Saint Joseph Mercy Brighton
Brighton, Michigan, 48114
University of Vermont Medical Center
Burlington, Vermont, 05401
University of Vermont and State Agricultural College
Burlington, Vermont, 05405
Saint James Community Hospital and Cancer Treatment Center
Butte, Montana, 59701
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, 83605
Illinois CancerCare-Canton
Canton, Illinois, 61520
IHA Hematology Oncology Consultants-Canton
Canton, Michigan, 48188
Saint Joseph Mercy Canton
Canton, Michigan, 48188
Aultman Health Foundation
Canton, Ohio, 44710
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
Caro Cancer Center
Caro, Michigan, 48723
Carson Tahoe Regional Medical Center
Carson City, Nevada, 89703
SIH Cancer Institute
Carterville, Illinois, 62918
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Sandra L Maxwell Cancer Center
Cedar City, Utah, 84720
Dayton Physicians LLC-Miami Valley South
Centerville, Ohio, 45459
Miami Valley Hospital South
Centerville, Ohio, 45459
Centralia Oncology Clinic
Centralia, Illinois, 62801
Ralph H Johnson VA Medical Center
Charleston, South Carolina, 29401
Sentara Martha Jefferson Hospital
Charlottesville, Virginia, 22901
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
IHA Hematology Oncology Consultants-Chelsea
Chelsea, Michigan, 48118
Saint Joseph Mercy Chelsea
Chelsea, Michigan, 48118
Cheyenne Regional Medical Center-West
Cheyenne, Wyoming, 82001
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, 60612
University of Illinois
Chicago, Illinois, 60612
Oncology Hematology Care Inc-Kenwood
Cincinnati, Ohio, 45236
Hematology Oncology Consultants-Clarkston
Clarkston, Michigan, 48346
Newland Medical Associates-Clarkston
Clarkston, Michigan, 48346
Prisma Health Cancer Institute - Laurens
Clinton, South Carolina, 29325
Billings Clinic-Cody
Cody, Wyoming, 82414
Kootenai Medical Center
Coeur d'Alene, Idaho, 83814
UCHealth Memorial Hospital Central
Colorado Springs, Colorado, 80909
Memorial Hospital North
Colorado Springs, Colorado, 80920
Baptist Memorial Hospital and Cancer Center-Golden Triangle
Columbus, Mississippi, 39705
Baptist Health Corbin
Corbin, Kentucky, 40701
Baylor University Medical Center
Dallas, Texas, 75246
Carle on Vermilion
Danville, Illinois, 61832
Geisinger Medical Center
Danville, Pennsylvania, 17822
Good Samaritan Hospital - Dayton
Dayton, Ohio, 45406
Miami Valley Hospital
Dayton, Ohio, 45409
Dayton Physician LLC-Miami Valley Hospital North
Dayton, Ohio, 45415
Miami Valley Hospital North
Dayton, Ohio, 45415
Beaumont Hospital - Dearborn
Dearborn, Michigan, 48124
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
Cancer Center of Colorado at Sloan's Lake
Denver, Colorado, 80204
National Jewish Health-Main Campus
Denver, Colorado, 80206
The Women's Imaging Center
Denver, Colorado, 80209
Colorado Blood Cancer Institute
Denver, Colorado, 80218
Presbyterian - Saint Lukes Medical Center - Health One
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Midtown
Denver, Colorado, 80218
SCL Health Saint Joseph Hospital
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Rose
Denver, Colorado, 80220
Rose Medical Center
Denver, Colorado, 80220
Western Surgical Care
Denver, Colorado, 80220
Ascension Saint John Hospital
Detroit, Michigan, 48236
Illinois CancerCare-Dixon
Dixon, Illinois, 61021
Prisma Health Cancer Institute - Easley
Easley, South Carolina, 29640
Great Lakes Cancer Management Specialists-Doctors Park
East China Township, Michigan, 48054
Pocono Medical Center
East Stroudsburg, Pennsylvania, 18301
Carle Physician Group-Effingham
Effingham, Illinois, 62401
Crossroads Cancer Center
Effingham, Illinois, 62401
Walter Knox Memorial Hospital
Emmett, Idaho, 83617
Mountain Blue Cancer Care Center - Swedish
Englewood, Colorado, 80113
Swedish Medical Center
Englewood, Colorado, 80113
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Deaconess Clinic Downtown
Evansville, Indiana, 47713
Fairbanks Memorial Hospital
Fairbanks, Alaska, 99701
Parkland Health Center - Farmington
Farmington, Missouri, 63640
Virginia Mason Federal Way Medical Center
Federal Way, Washington, 98002
Armes Family Cancer Center
Findlay, Ohio, 45840
Blanchard Valley Hospital
Findlay, Ohio, 45840
Orion Cancer Care
Findlay, Ohio, 45840
Augusta Health Center for Cancer and Blood Disorders
Fishersville, Virginia, 22939
Hunterdon Medical Center
Flemington, New Jersey, 08822
Genesee Cancer and Blood Disease Treatment Center
Flint, Michigan, 48503
Genesee Hematology Oncology PC
Flint, Michigan, 48503
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
Broward Health Medical Center
Fort Lauderdale, Florida, 33316
Parkview Hospital Randallia
Fort Wayne, Indiana, 46805
Parkview Regional Medical Center
Fort Wayne, Indiana, 46845
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Dayton Physicians LLC-Atrium
Franklin, Ohio, 45005
University of Florida Health Science Center - Gainesville
Gainesville, Florida, 32610
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Western Illinois Cancer Treatment Center
Galesburg, Illinois, 61401
University of Texas Medical Branch
Galveston, Texas, 77555-0565
Tacoma/Valley Radiation Oncology Centers-Gig Harbor
Gig Harbor, Washington, 98332
MultiCare Gig Harbor Medical Park
Gig Harbor, Washington, 98335
Glens Falls Hospital
Glens Falls, New York, 12801
National Jewish Health-Western Hematology Oncology
Golden, Colorado, 80401
Saint Mary's Hospital and Regional Medical Center
Grand Junction, Colorado, 81501
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, 59405
Great Falls Clinic
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
East Carolina University
Greenville, North Carolina, 27834
Dayton Physicians LLC-Wayne
Greenville, Ohio, 45331
Wayne Hospital
Greenville, Ohio, 45331
Prisma Health Cancer Institute - Butternut
Greenville, South Carolina, 29605
Prisma Health Cancer Institute - Faris
Greenville, South Carolina, 29605
Prisma Health Greenville Memorial Hospital
Greenville, South Carolina, 29605
Prisma Health Cancer Institute - Eastside
Greenville, South Carolina, 29615
Prisma Health Cancer Institute - Greer
Greer, South Carolina, 29650
Academic Hematology Oncology Specialists
Grosse Pointe Woods, Michigan, 48236
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Grosse Pointe Woods, Michigan, 48236
Michigan Breast Specialists-Grosse Pointe Woods
Grosse Pointe Woods, Michigan, 48236
The Cancer Institute of New Jersey Hamilton
Hamilton, New Jersey, 08690
Geisinger Medical Center-Cancer Center Hazleton
Hazleton, Pennsylvania, 18201
Lehigh Valley Hospital-Hazleton
Hazleton, Pennsylvania, 18201
Saint Peter's Community Hospital
Helena, Montana, 59601
Cancer and Blood Specialists-Henderson
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada - Henderson
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada-Horizon Ridge
Henderson, Nevada, 89052
Las Vegas Cancer Center-Henderson
Henderson, Nevada, 89052
OptumCare Cancer Care at Seven Hills
Henderson, Nevada, 89052
21st Century Oncology-Henderson
Henderson, Nevada, 89074
Comprehensive Cancer Centers of Nevada-Southeast Henderson
Henderson, Nevada, 89074
Las Vegas Urology - Green Valley
Henderson, Nevada, 89074
Las Vegas Urology - Pebble
Henderson, Nevada, 89074
Urology Specialists of Nevada - Green Valley
Henderson, Nevada, 89074
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida, 33021
Bayshore Community Hospital
Holmdel, New Jersey, 07733
Franciscan Health Indianapolis
Indianapolis, Indiana, 46237
Allegiance Health
Jackson, Michigan, 49201
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Capital Region Southwest Campus
Jefferson City, Missouri, 65109
Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas, 72401
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Northwest Cancer Clinic
Kennewick, Washington, 99336
Greater Dayton Cancer Center
Kettering, Ohio, 45409
First Dayton Cancer Care
Kettering, Ohio, 45420
Kettering Medical Center
Kettering, Ohio, 45429
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Kingman Regional Medical Center
Kingman, Arizona, 86401
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin, 54601
Good Samaritan Medical Center
Lafayette, Colorado, 80026
Sparrow Hospital
Lansing, Michigan, 48912
Las Vegas Urology - Pecos
Las Vegas, Nevada, 89074
Desert West Surgery
Las Vegas, Nevada, 89102
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
Hope Cancer Care of Nevada
Las Vegas, Nevada, 89103
Cancer and Blood Specialists-Shadow
Las Vegas, Nevada, 89106
OptumCare Cancer Care at Oakey
Las Vegas, Nevada, 89106
Radiation Oncology Centers of Nevada Central
Las Vegas, Nevada, 89106
Urology Specialists of Nevada - Central
Las Vegas, Nevada, 89106
21st Century Oncology
Las Vegas, Nevada, 89109
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
Las Vegas, Nevada, 89109
Sunrise Hospital and Medical Center
Las Vegas, Nevada, 89109
HealthCare Partners Medical Group Oncology/Hematology-San Martin
Las Vegas, Nevada, 89113
Las Vegas Prostate Cancer Center
Las Vegas, Nevada, 89113
Las Vegas Urology - Sunset
Las Vegas, Nevada, 89113
Radiation Oncology Centers of Nevada Southeast
Las Vegas, Nevada, 89119
Cancer Therapy and Integrative Medicine
Las Vegas, Nevada, 89121
21st Century Oncology-Vegas Tenaya
Las Vegas, Nevada, 89128
Ann M Wierman MD LTD
Las Vegas, Nevada, 89128
Cancer and Blood Specialists-Tenaya
Las Vegas, Nevada, 89128
Comprehensive Cancer Centers of Nevada - Northwest
Las Vegas, Nevada, 89128
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
Las Vegas, Nevada, 89128
Las Vegas Urology - Cathedral Rock
Las Vegas, Nevada, 89128
Las Vegas Urology - Smoke Ranch
Las Vegas, Nevada, 89128
OptumCare Cancer Care at MountainView
Las Vegas, Nevada, 89128
Urology Specialists of Nevada - Northwest
Las Vegas, Nevada, 89128
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
Las Vegas, Nevada, 89135
Comprehensive Cancer Centers of Nevada - Town Center
Las Vegas, Nevada, 89144
Comprehensive Cancer Centers of Nevada-Summerlin
Las Vegas, Nevada, 89144
Summerlin Hospital Medical Center
Las Vegas, Nevada, 89144
Las Vegas Cancer Center-Medical Center
Las Vegas, Nevada, 89148-2405
21st Century Oncology-Fort Apache
Las Vegas, Nevada, 89148
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89148
OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada, 89148
Urology Specialists of Nevada - Southwest
Las Vegas, Nevada, 89148
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
Las Vegas, Nevada, 89149
Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada, 89169
University Cancer Center
Las Vegas, Nevada, 89169
UTMB Cancer Center at Victory Lakes
League City, Texas, 77573
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Geisinger Medical Oncology-Lewisburg
Lewisburg, Pennsylvania, 17837
Lewistown Hospital
Lewistown, Pennsylvania, 17044
Baptist Health Lexington
Lexington, Kentucky, 40503
Rocky Mountain Cancer Centers-Littleton
Littleton, Colorado, 80120
Hope Cancer Clinic
Livonia, Michigan, 48154
Saint Mary Mercy Hospital
Livonia, Michigan, 48154
Logan Regional Hospital
Logan, Utah, 84321
Veterans Affairs Loma Linda Healthcare System
Loma Linda, California, 92357
Rocky Mountain Cancer Centers-Sky Ridge
Lone Tree, Colorado, 80124
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Baptist Health Louisville
Louisville, Kentucky, 40207
McKee Medical Center
Loveland, Colorado, 80539
Virginia Mason Lynnwood Medical Center
Lynnwood, Washington, 98036
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Great Lakes Cancer Management Specialists-Macomb Medical Campus
Macomb, Michigan, 48044
Michigan Breast Specialists-Macomb Township
Macomb, Michigan, 48044
Baptist Health Madisonville/Merle Mahr Cancer Center
Madisonville, Kentucky, 42431
Southern Ocean County Medical Center
Manahawkin, New Jersey, 08050
Mayo Clinic Health Systems-Mankato
Mankato, Minnesota, 56001
Saint Mary's Oncology/Hematology Associates of Marlette
Marlette, Michigan, 48453
UP Health System Hematology Oncology Marquette
Marquette, Michigan, 49855
UP Health System Marquette
Marquette, Michigan, 49855
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938
Loyola University Medical Center
Maywood, Illinois, 60153
Marjorie Weinberg Cancer Center at Loyola-Gottlieb
Melrose Park, Illinois, 60160
Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, Tennessee, 38120
Baptist Memorial Hospital for Women
Memphis, Tennessee, 38120
Idaho Urologic Institute-Meridian
Meridian, Idaho, 83642
Woodland Cancer Care Center
Michigan City, Indiana, 46360
Middlesex Hospital
Middletown, Connecticut, 06457
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215
Memorial Regional Cancer Center Day Road
Mishawaka, Indiana, 46545
Community Medical Hospital
Missoula, Montana, 59804
Trinity Medical Center
Moline, Illinois, 61265
Franciscan Health Mooresville
Mooresville, Indiana, 46158
Virtua Memorial
Mount Holly, New Jersey, 08060
Intermountain Medical Center
Murray, Utah, 84107
Saint Alphonsus Medical Center-Nampa
Nampa, Idaho, 83686
Jersey Shore Medical Center
Neptune City, New Jersey, 07753
Baptist Memorial Hospital and Cancer Center-Union County
New Albany, Mississippi, 38652
Ochsner Medical Center Jefferson
New Orleans, Louisiana, 70121
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
Chancellor Center for Oncology
Newburgh, Indiana, 47630
Sentara Norfolk General Hospital
Norfolk, Virginia, 23507
McKay-Dee Hospital Center
Ogden, Utah, 84403
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Nebraska Methodist Hospital
Omaha, Nebraska, 68114
Saint Alphonsus Medical Center-Ontario
Ontario, Oregon, 97914
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
Baptist Memorial Hospital and Cancer Center-Oxford
Oxford, Mississippi, 38655
Baptist Health Paducah
Paducah, Kentucky, 42003
Hope Cancer Care of Nevada-Pahrump
Pahrump, Nevada, 89048
Singing River Hospital
Pascagoula, Mississippi, 39581
Illinois CancerCare-Pekin
Pekin, Illinois, 61554
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
Pekin, Illinois, 61554
Memorial Hospital West
Pembroke Pines, Florida, 33028
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
Peoria, Illinois, 61615
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
OSF Saint Francis Medical Center
Peoria, Illinois, 61637
Illinois CancerCare-Peru
Peru, Illinois, 61354
Valley Radiation Oncology
Peru, Illinois, 61354
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
21st Century Oncology-Pontiac
Pontiac, Michigan, 48341
Hope Cancer Center
Pontiac, Michigan, 48341
Newland Medical Associates-Pontiac
Pontiac, Michigan, 48341
Saint Joseph Mercy Oakland
Pontiac, Michigan, 48341
Huron Medical Center PC
Port Huron, Michigan, 48060
Lake Huron Medical Center
Port Huron, Michigan, 48060
Jefferson Healthcare
Port Townsend, Washington, 98368
Kootenai Cancer Center
Post Falls, Idaho, 83854
Geisinger Cancer Services-Pottsville
Pottsville, Pennsylvania, 17901
Vassar Brothers Medical Center
Poughkeepsie, New York, 12601
Peninsula Cancer Center
Poulsbo, Washington, 98370
Illinois CancerCare-Princeton
Princeton, Illinois, 61356
Utah Valley Regional Medical Center
Provo, Utah, 84604
MultiCare Good Samaritan Hospital
Puyallup, Washington, 98372
Tacoma/Valley Radiation Oncology Centers-Puyallup
Puyallup, Washington, 98372
Eisenhower Medical Center
Rancho Mirage, California, 92270
Riverview Medical Center/Booker Cancer Center
Red Bank, New Jersey, 07701
Renown Regional Medical Center
Reno, Nevada, 89502
About this study
Official title: Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
This randomized phase III trial studies how well management of a tobacco treatment intervention works in reducing surgical complications in patients with newly diagnosed lung cancer who smoke cigarettes. Management of a tobacco treatment intervention compares varenicline (a drug that reduces the craving and withdrawal symptoms that occur with abstinence from nicotine) and behavioral interventions (consisting of a brief clinician-delivered intervention and tobacco quitline [tobacco cessation service available through a toll-free telephone number] follow-up) with placebo (a pill with no active medication) along with similar behavioral interventions. It is not yet known whether management of a tobacco treatment intervention is more effective in reducing surgical complications than placebo.
Read the detailed description
PRIMARY OBJECTIVES:
- To determine if varenicline plus a behavioral intervention consisting of a brief clinician-delivered intervention and tobacco quitline follow-up, decreases postsurgical complications through 24 weeks after surgery when compared to placebo plus the behavioral intervention in lung cancer patients who undergo surgery and are motivated to stop smoking.
SECONDARY OBJECTIVES:
- To compare changes from baseline to 12 and 24 weeks after surgery in the patient quality of life (Linear Analogue Self-Assessment [LASA]-12) domains between the intervention (varenicline) and control group (placebo).
II. To compare changes from baseline to 6, 12 and 24 weeks after surgery in the patient quality of life related domains (LASA) for the Patient Health Questionnaire (PHQ)-9 and Smoking Self Efficacy Questionnaire (SEQ)12 between the intervention and control groups.
III. To compare the proportion of patients 12 weeks and 24 weeks after surgery who endorse ("Was It Worth It") each treatment (intervention versus [vs] control groups).
IV. To compare post-operative care (as measured by length of hospital and high dependency unit stay) between the intervention and control groups.
- To compare treatment adherence between the intervention and control groups. VI. To compare rates of smoking abstinence between the intervention and control groups as a covariate of the primary outcome only.
- Conditions
- Lung Carcinoma
- Being tested
- Varenicline, Placebo, Tobacco Cessation Counseling
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VareniclineDrug
Given PO
PlaceboDrug
Given PO
Tobacco Cessation CounselingOther
Complete counseling session
| Study group | Role | What they receive |
|---|---|---|
| Intervention group (varenicline and behavioral intervention) | Experimental | Patients receive varenicline PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult. Receives: Drug: Varenicline; Other: Tobacco Cessation Counseling |
| Control group (placebo and behavioral intervention) | Placebo comparator | Patients receive placebo PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult. Receives: Drug: Placebo; Other: Tobacco Cessation Counseling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality
Number of patients that died within 30 days of surgery
Measured: Up to 30 days post-surgery
Re-hospitalization
Number of patients re-hospitalized within 30 days of surgery
Measured: Up to 30 days post-surgery
Number of Paticipants With Incidence of Pulmonary Complications
Surgical complication incidence rates at 24 weeks after surgery will be compared between the intervention vs. control groups using a Fisher's exact test. Logistic regression models will supplement the univariate analysis, using complication incidence as the dependent variable and will include smoking status at the time of surgery as an independent variable and also adjust for age, gender, Fagerström Test for Nicotine Dependence (FTND), time between randomization and surgery, and presence of adjuvant chemotherapy and/or radiation therapy. We will also explore the collinear relationship between arm and smoking status to see whether they can be included together in the logistic models.
Measured: Up to 24 weeks post-surgery
Number of Participants With Incidence of Intensive Care Unit Readmission
Surgical complication incidence rates at 24 weeks after surgery will be compared between the intervention vs. control groups using a Fisher's exact test. Logistic regression models will supplement the univariate analysis, using complication incidence as the dependent variable and will include smoking status at the time of surgery as an independent variable and also adjust for age, gender, FTND, time between randomization and surgery, and presence of adjuvant chemotherapy and/or radiation therapy. A separate logistic model will be created including treatment arm instead of smoking status. We will also explore the collinear relationship between arm and smoking status to see whether they can be included together in the logistic models.
Measured: Up to 24 weeks post-surgery
Number of Participants With Incidence of Unspecified Wound Infection
Surgical complication incidence rates at 24 weeks after surgery will be compared between the intervention vs. control groups using a Fisher's exact test. Logistic regression models will supplement the univariate analysis, using complication incidence as the dependent variable and will include smoking status at the time of surgery as an independent variable and also adjust for age, gender, FTND, time between randomization and surgery, and presence of adjuvant chemotherapy and/or radiation therapy. A separate logistic model will be created including treatment arm instead of smoking status. We will also explore the collinear relationship between arm and smoking status to see whether they can be included together in the logistic models.
Measured: Up to 24 weeks post-surgery
Number of Participants With Incidence of Anastomotic Failure
Surgical complication incidence rates at 24 weeks after surgery will be compared between the intervention vs. control groups using a Fisher's exact test. Logistic regression models will supplement the univariate analysis, using complication incidence as the dependent variable and will include smoking status at the time of surgery as an independent variable and also adjust for age, gender, FTND, time between randomization and surgery, and presence of adjuvant chemotherapy and/or radiation therapy. A separate logistic model will be created including treatment arm instead of smoking status. We will also explore the collinear relationship between arm and smoking status to see whether they can be included together in the logistic models.
Measured: Up to 24 weeks post-surgery
Secondary outcomes (9)
Change in QOL as Measured by the LASA-12, PHQ-9, SEQ-12
Analysis of covariance and linear mixed model repeated measures analysis will be used for each assessment domain (LASA-12, PHQ-9, SEQ12).
Measured: Baseline up to 24 weeks after surgery
Change in QOL as Measured by Was It Worth It Assessments
Measured: At 12 weeks after surgery
Change in QOL as Measured by Was It Worth It Assessments
Measured: At 24 weeks after surgery
Length of Hospital Stay
Logrank testing of Kaplan-Meier estimates will be used for length of hospital stay and supplemented by Cox models to control for concomitant covariates.
Measured: The time from surgery until the patient is released from the hospital
Length of High Dependency Unit Stay
Logrank testing of Kaplan-Meier estimates will be used for length of high dependency unit stay and supplemented by Cox models to control for concomitant covariates.
Measured: The time from surgery until the patient is released from the hospital
Expanded Complication Rate
Measured: Up to 1 year
Treatment Adherence Rates Related to Visits, Medication Compliance, Quitline Usage, and Surgeon Teachable Moment Delivery
Measured: Up to 12 weeks
Smoking Abstinence Rates as Measured by Self-report
Measured: Up to 12 weeks
Smoking Abstinence Rates as Measured by Salivary Cotinine Testing
Measured: Up to 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2016 (estimated)
- Study start29 Sep 2017
- Primary completion28 May 2021
- Study completion15 Apr 2022
Why it stopped: Slow accrual
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Lung CarcinomaStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 23 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI), Pfizer
- Responsible party
- Sponsor
- Investigators
- Ivana Croghan, PhD, Study chair, Mayo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02856581
- Sponsor's protocol ID
- A211401
- Other IDs
- NCI-2016-00438
- Status last verified
- Jun 2022
- First submitted
- 1 Aug 2016
- Last updated
- 27 Jul 2022
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Jul 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
- ClinicalTrials.gov ID
- NCT02856581
- Acronym / sponsor ID
- A211401
- Conditions
- Lung Carcinoma
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Slow accrual
- Enrolment
- 23 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI), Pfizer
- Study start
- 29 Sep 2017 (actual)
- Primary completion
- 28 May 2021 (actual)
- Study completion
- 15 Apr 2022 (actual)
- First posted
- 5 Aug 2016 (estimated)
- Results
- Posted 24 Jun 2022
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized phase III trial studies how well management of a tobacco treatment intervention works in reducing surgical complications in patients with newly diagnosed lung cancer who smoke cigarettes. Management of a tobacco treatment intervention compares varenicline (a drug that reduces the craving and withdrawal symptoms that occur with abstinence from nicotine) and behavioral interventions (consisting of a brief clinician-delivered intervention and tobacco quitline [tobacco cessation service available through a toll-free telephone number] follow-up) with placebo (a pill with no active medication) along with similar behavioral interventions. It is not yet known whether management of a tobacco treatment intervention is more effective in reducing surgical complications than placebo.
Detailed description
PRIMARY OBJECTIVES:
- To determine if varenicline plus a behavioral intervention consisting of a brief clinician-delivered intervention and tobacco quitline follow-up, decreases postsurgical complications through 24 weeks after surgery when compared to placebo plus the behavioral intervention in lung cancer patients who undergo surgery and are motivated to stop smoking.
SECONDARY OBJECTIVES:
- To compare changes from baseline to 12 and 24 weeks after surgery in the patient quality of life (Linear Analogue Self-Assessment [LASA]-12) domains between the intervention (varenicline) and control group (placebo).
II. To compare changes from baseline to 6, 12 and 24 weeks after surgery in the patient quality of life related domains (LASA) for the Patient Health Questionnaire (PHQ)-9 and Smoking Self Efficacy Questionnaire (SEQ)12 between the intervention and control groups.
III. To compare the proportion of patients 12 weeks and 24 weeks after surgery who endorse ("Was It Worth It") each treatment (intervention versus [vs] control groups).
IV. To compare post-operative care (as measured by length of hospital and high dependency unit stay) between the intervention and control groups.
- To compare treatment adherence between the intervention and control groups. VI. To compare rates of smoking abstinence between the intervention and control groups as a covariate of the primary outcome only.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention group (varenicline and behavioral intervention) | Experimental | Drug: Varenicline, Other: Tobacco Cessation CounselingPatients receive varenicline PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult. |
| Control group (placebo and behavioral intervention) | Placebo comparator | Drug: Placebo, Other: Tobacco Cessation CounselingPatients receive placebo PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VareniclineGiven PO | Drug | Intervention group (varenicline and behavioral intervention) |
| PlaceboGiven PO | Drug | Control group (placebo and behavioral intervention) |
| Tobacco Cessation CounselingComplete counseling session | Other | Control group (placebo and behavioral intervention), Intervention group (varenicline and behavioral intervention) |
Primary outcome
Mortality
Time frame: Up to 30 days post-surgery
Number of patients that died within 30 days of surgery
Re-hospitalization
Time frame: Up to 30 days post-surgery
Number of patients re-hospitalized within 30 days of surgery
Number of Paticipants With Incidence of Pulmonary Complications
Time frame: Up to 24 weeks post-surgery
Surgical complication incidence rates at 24 weeks after surgery will be compared between the intervention vs. control groups using a Fisher's exact test. Logistic regression models will supplement the univariate analysis, using complication incidence as the dependent variable and will include smoking status at the time of surgery as an independent variable and also adjust for age, gender, Fagerström Test for Nicotine Dependence (FTND), time between randomization and surgery, and presence of adjuvant chemotherapy and/or radiation therapy. We will also explore the collinear relationship between arm and smoking status to see whether they can be included together in the logistic models.
Number of Participants With Incidence of Intensive Care Unit Readmission
Time frame: Up to 24 weeks post-surgery
Surgical complication incidence rates at 24 weeks after surgery will be compared between the intervention vs. control groups using a Fisher's exact test. Logistic regression models will supplement the univariate analysis, using complication incidence as the dependent variable and will include smoking status at the time of surgery as an independent variable and also adjust for age, gender, FTND, time between randomization and surgery, and presence of adjuvant chemotherapy and/or radiation therapy. A separate logistic model will be created including treatment arm instead of smoking status. We will also explore the collinear relationship between arm and smoking status to see whether they can be included together in the logistic models.
Number of Participants With Incidence of Unspecified Wound Infection
Time frame: Up to 24 weeks post-surgery
Surgical complication incidence rates at 24 weeks after surgery will be compared between the intervention vs. control groups using a Fisher's exact test. Logistic regression models will supplement the univariate analysis, using complication incidence as the dependent variable and will include smoking status at the time of surgery as an independent variable and also adjust for age, gender, FTND, time between randomization and surgery, and presence of adjuvant chemotherapy and/or radiation therapy. A separate logistic model will be created including treatment arm instead of smoking status. We will also explore the collinear relationship between arm and smoking status to see whether they can be included together in the logistic models.
Number of Participants With Incidence of Anastomotic Failure
Time frame: Up to 24 weeks post-surgery
Surgical complication incidence rates at 24 weeks after surgery will be compared between the intervention vs. control groups using a Fisher's exact test. Logistic regression models will supplement the univariate analysis, using complication incidence as the dependent variable and will include smoking status at the time of surgery as an independent variable and also adjust for age, gender, FTND, time between randomization and surgery, and presence of adjuvant chemotherapy and/or radiation therapy. A separate logistic model will be created including treatment arm instead of smoking status. We will also explore the collinear relationship between arm and smoking status to see whether they can be included together in the logistic models.
9 secondary outcomes
Change in QOL as Measured by the LASA-12, PHQ-9, SEQ-12
Time frame: Baseline up to 24 weeks after surgery
Change in QOL as Measured by Was It Worth It Assessments
Time frame: At 12 weeks after surgery
Change in QOL as Measured by Was It Worth It Assessments
Time frame: At 24 weeks after surgery
Length of Hospital Stay
Time frame: The time from surgery until the patient is released from the hospital
Length of High Dependency Unit Stay
Time frame: The time from surgery until the patient is released from the hospital
Expanded Complication Rate
Time frame: Up to 1 year
Treatment Adherence Rates Related to Visits, Medication Compliance, Quitline Usage, and Surgeon Teachable Moment Delivery
Time frame: Up to 12 weeks
Smoking Abstinence Rates as Measured by Self-report
Time frame: Up to 12 weeks
Smoking Abstinence Rates as Measured by Salivary Cotinine Testing
Time frame: Up to 12 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jul 2022.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Lung Carcinoma
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ivana Croghan, PhD study chair
Mayo
374 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Varenicline and Tobacco Cessation Counseling in people with Lung Carcinoma, run by Alliance for Clinical Trials in Oncology at 374 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 27 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 374 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 24 Jun 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality (time frame: Up to 30 days post-surgery). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2022; AzTrials last refreshed its copy on 8 Nov 2026.